| 51 |
27895112 | Hepatic Dipeptidyl Peptidase-4 Controls Pharmacokinetics of Vildagliptin In Vivo. | 2017 Feb |
2 |
| 52 |
27939504 | Anti-inflammatory effects on ischemia/reperfusion-injured lung transplants by the cluster of differentiation 26/dipeptidylpeptidase 4 (CD26/DPP4) inhibitor vildagliptin. | 2017 Mar |
1 |
| 53 |
28093996 | Challenges Related to Glycemic Control in Type 2 Diabetes Mellitus Patients. | 2017 |
1 |
| 54 |
28182722 | Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. | 2017 |
1 |
| 55 |
28367418 | Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs. | 2017 Apr-Jun |
1 |
| 56 |
28403729 | Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. | 2017 Apr |
1 |
| 57 |
28408838 | DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes. | 2017 |
1 |
| 58 |
28489279 | Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. | 2017 May 10 |
1 |
| 59 |
28631242 | Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis. | 2017 Aug |
2 |
| 60 |
28983844 | The Role of Vildagliptin in the Therapy of Type 2 Diabetic Patients with Renal Dysfunction. | 2017 Dec |
1 |
| 61 |
29632607 | Ten Years of Vildagliptin. | 2017 Aug |
1 |
| 62 |
29632608 | The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration. | 2017 Aug |
1 |
| 63 |
29632609 | Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes. | 2017 Aug |
2 |
| 64 |
29632610 | Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance. | 2017 Aug |
2 |
| 65 |
26786576 | A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes. | 2016 Apr |
2 |
| 66 |
26824365 | Novel Therapeutic Approaches in Diabetes. | 2016 |
1 |
| 67 |
26855580 | Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients? | 2016 |
2 |
| 68 |
26871938 | Development and validation of a cyclodextrin-modified capillary electrophoresis method for the enantiomeric separation of vildagliptin enantiomers. | 2016 May |
1 |
| 69 |
26950829 | Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea. | 2016 Jun |
2 |
| 70 |
27031194 | Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. | 2016 Aug |
2 |
| 71 |
27048342 | Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | 2016 |
1 |
| 72 |
27067162 | Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. | 2016 May |
1 |
| 73 |
27193434 | Switching from subcutaneous insulin injection to oral vildagliptin administration in hemodialysis patients with type 2 diabetes: a pilot study. | 2016 Aug |
1 |
| 74 |
27207543 | Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist. | 2016 Aug |
3 |
| 75 |
27209165 | MicroRNA expression in the vildagliptin-treated two- and three-dimensional HepG2 cells. | 2016 Jun |
1 |
| 76 |
27321385 | Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus. | 2016 Aug 31 |
1 |
| 77 |
27376699 | Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy. | 2016 Jul 4 |
1 |
| 78 |
27520566 | Vildagliptin-induced acute lung injury: a case report. | 2016 Aug 12 |
2 |
| 79 |
27598511 | Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes. | 2016 Dec |
1 |
| 80 |
27642611 | Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients. | 2016 |
1 |
| 81 |
27759084 | Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells. | 2016 Oct 19 |
3 |
| 82 |
23665884 | Vildagliptin with metformin once-daily regimen-insights from a single-center analysis. | 2015 May-Jun |
2 |
| 83 |
25331711 | Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. | 2015 Jan |
1 |
| 84 |
25452780 | Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals. | 2015 Jan |
1 |
| 85 |
25597851 | Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liver. | 2015 Apr |
4 |
| 86 |
25664602 | Effect of vildagliptin on hepatic steatosis. | 2015 Apr |
1 |
| 87 |
25687897 | A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. | 2015 Feb 16 |
2 |
| 88 |
25931826 | Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients. | 2015 |
1 |
| 89 |
26089691 | Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease. | 2015 |
1 |
| 90 |
26166078 | DPP-4 Inhibitor Reduces Central Blood Pressure in a Diabetic and Hypertensive Patient: A Case Report. | 2015 Jul |
2 |
| 91 |
26173919 | Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. | 2015 Oct |
1 |
| 92 |
26301063 | Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study. | 2015 Aug |
1 |
| 93 |
26312070 | Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension. | 2015 |
1 |
| 94 |
26316706 | Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus. | 2015 |
1 |
| 95 |
26517136 | Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin. | 2015 |
1 |
| 96 |
26587020 | Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin. | 2015 |
1 |
| 97 |
26603933 | Glucagon-like peptide 1 (GLP-1)-based therapy upregulates LXR-ABCA1/ABCG1 cascade in adipocytes. | 2015 Dec 25 |
1 |
| 98 |
26816911 | Evaluation of Anti Cancer Effects of DPP-4 Inhibitors in Colon Cancer- An Invitro Study. | 2015 Dec |
1 |
| 99 |
27382546 | Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan. | 2015 |
2 |
| 100 |
24279801 | Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial. | 2014 Jan |
1 |